Experimental Seladelpar Shows Notable Advancements in Liver Disease and Alleviates Itching in Primary Biliary Cholangitis.

The SUPERNOVA Phase III trial for the long-acting antibody sipavibart successfully met its primary goals in preventing COVID-19 among immunocompromised patients.

Recludix Pharma Shares Data Showing Oral STAT3 Inhibitors Offer Unique Efficacy and Safety in Th17-Driven Skin Inflammation Preclinical Models during Oral Session at SID Annual Meeting.

Apogee Starts Phase 2 Trial of APG777 in Atopic Dermatitis with First Patient Dosed. APG777 is a new long-acting IL-13 inhibitor for treating Atopic Dermatitis and various inflammatory conditions.

Voyager Therapeutics, Inc. revealed that the initial subjects have been administered doses in a Phase 1a single ascending dose study of VY-TAU01.

Tourmaline Bio Begins Clinical Trials for TOUR006 in Cardiovascular Disease; First Patient Treated in Phase 2 TRANQUILITY Study.

CASI Pharmaceuticals Gets FDA Approval For Investigational New Drug CID-103 In Treating Immune Thrombocytopenia (ITP).

Ractigen Therapeutics Gains NMPA Clearance to Begin Phase 1 Trials of RAG-17 in Chinese SOD1-ALS Patients.

With Weekly Dosing, Insulin Efsitora Alfa Achieves A1C Reduction and Matches Safety of Daily Insulin.

Ionis Pharmaceuticals, Inc. reported favorable primary results from the HALOS Phase 1/2a open-label trial of ION582 for Angelman syndrome.

Ionis Pharmaceuticals, Inc. and Biogen Inc. have decided to discontinue the development of BIIB105 (ION541) following the initial outcomes from the Phase 1/2 ALSpire trial.

Carisma Therapeutics reports initial patient dosed in Phase 1 study of CT-0525, an innovative HER2-focused CAR-monocyte therapy.